Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | APP | P05067 | 3/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3522307 | 0.88 | MEN1 (0.34) | MEN1KMT2AALDH1A1APPEPHX1 | |
| SCHEMBL3522311 | 0.88 | MEN1 (0.34) | MEN1KMT2AALDH1A1APPEPHX1 | |
| SCHEMBL3522308 | 0.88 | MEN1 (0.34) | MEN1KMT2AALDH1A1APPEPHX1 | |
| SCHEMBL2165649 | 0.87 | MEN1 (0.46) | MEN1KMT2AALDH1A1EPHX1KDM4E | |
| SCHEMBL1206815 | 0.82 | MEN1 (0.40) | MEN1KMT2AALDH1A1KDM4EHPGD | |
| SCHEMBL5231447 | 0.82 | MEN1 (0.40) | MEN1KMT2AALDH1A1KDM4EHPGD | |
| SCHEMBL2165871 | 0.78 | GPR35 (0.41) | MEN1KMT2AALDH1A1KDM4EHPGD | |
| SCHEMBL2166096 | 0.76 | MEN1 (0.43) | MEN1KMT2AALDH1A1KDM4EHPGD | |
| SCHEMBL2166094 | 0.76 | MEN1 (0.43) | MEN1KMT2AALDH1A1KDM4EHPGD | |
| SCHEMBL4497968 | 0.76 | F2 (0.34) | ALDH1A1APPCFTRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528129-B2 | CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-05 | — | — | US | disclosed |
| US-20060252931-A1 | New CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252931-A1 | New CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | MEN1 678/4885KMT2A 4813/4885ALDH1A1 1872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.